
    
      In this phase II trial, patients will be randomly assigned, in a 1:1 ratio, to standard
      adjuvant or neoadjuvant chemotherapy with the GnRH agonist goserelin (goserelin group) or to
      chemotherapy without goserelin (chemotherapy alone group).

      For Patients randomly assigned to the goserelin group, goserelin at a dose of 3.6 mg will be
      administered subcutaneously every 4 weeks beginning 1 week before the initial chemotherapy
      dose and will be continued to within 2 weeks before or after the final chemotherapy dose.

      Follow up: All patients will be followed for at least 1 year clinically monthly and by
      laboratory assessment by hormonal profile (FSH, LH, E2) every 6 months.
    
  